News
TXMD
2.040
-3.32%
-0.070
TherapeuticsMD Inc. Stock Sheds 5.5%, Underperforms Market
Dow Jones · 3d ago
Weekly Report: what happened at TXMD last week (0420-0424)?
Weekly Report · 4d ago
Weekly Report: what happened at TXMD last week (0413-0417)?
Weekly Report · 04/20 10:07
Weekly Report: what happened at TXMD last week (0406-0410)?
Weekly Report · 04/13 10:10
TherapeuticsMD Inc. Stock Rallies 10.0%, Outperforms Market
Dow Jones · 04/06 20:32
Weekly Report: what happened at TXMD last week (0330-0403)?
Weekly Report · 04/06 10:10
TherapeuticsMD Explains Brief Delay In Annual Filing
TipRanks · 04/01 15:39
TherapeuticsMD delays 2025 10-K after filing omits auditor report
Reuters · 04/01 10:08
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy
TipRanks · 03/31 00:12
TherapeuticsMD Q4 EPS $(0.06) Down From $0.01 YoY, Sales $893.000K Up From $667.000K YoY
Benzinga · 03/30 22:10
TherapeuticsMD Inc. Stock Slides 5.2%, Underperforms Market
Dow Jones · 03/30 20:34
TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year
TipRanks · 03/30 20:23
Therapeutics MD reports FY results
Seeking Alpha · 03/30 20:15
*TherapeuticsMD Won't Disclose Further Developments Unless and Until Determined Disclosure Is Appropriate or Necessary >TXMD
Dow Jones · 03/30 20:12
*TherapeuticsMD Has Not Established a Timetable for Completion of This Exploration Process >TXMD
Dow Jones · 03/30 20:12
*TherapeuticsMD Continues to Evaluate a Variety of Strategic Alternatives >TXMD
Dow Jones · 03/30 20:11
TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million
Reuters · 03/30 20:07
THERAPEUTICSMD ANNOUNCES FULL YEAR 2025 FINANCIAL RESULTS
Reuters · 03/30 20:05
Press Release: TherapeuticsMD Announces Full Year 2025 Financial Results
Dow Jones · 03/30 20:05
TherapeuticsMD Announces Full Year 2025 Financial Results
Barchart · 03/30 15:05
More
Webull provides a variety of real-time TXMD stock news. You can receive the latest news about Therapeuticsmd Inc through multiple platforms. This information may help you make smarter investment decisions.
About TXMD
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).